ASCO2021: Devaruzumab can improve the 5-year survival and progression-free survival of patients with unresectable stage III NSCLC

PACIFIC III trials to study the lack of progress after chemotherapy unresectable stage III non-small cell lung cancer ( NSCLC ) patients with at Dewa Lu monoclonal safety and effectiveness of the results made now Dewa Lu mAb significantly increase the total Lifetime (OS) and progression-free survival (PFS)
.

In addition, it exhibits easy-to- manage safety and does not adversely affect patient-reported results

PACIFIC III trials to study the lack of progress after chemotherapy unresectable stage III non-small cell lung cancer ( NSCLC ) patients with at Dewa Lu monoclonal safety and effectiveness of the results made now Dewa Lu mAb significantly increase the total Lifetime (OS) and progression-free survival (PFS)

Devaruzumab

Overall survival data

Overall survival data

The results showed that long-term, consolidating solid Dewa Lu monoclonal continue to benefit
.

In terms of weaknesses , we know , many patients fail in this study did not continue to receive immune therapy , which began a question , that is, in the current metastatic non-small cell lung cancer (NSCLC) in patients with widely used immunotherapy era, whether A more appropriate control group will have similar OS results

The results showed that long-term, consolidating solid Dewa Lu monoclonal continued to benefit from consolidating solid Dewa Lu monoclonal continued to benefit from solid Dewa Lu mAb continued

In addition, there are no biomarker options in this trial, but most of the benefits observed are limited to patients expressing PD-L1

Progression-free survival data

Progression-free survival data

However, there are still some shortcomings in the current research.
Dr.
Spiegel and others are investigating the joint research of the PACIFIC regimen with different radiochemotherapy regimens and other drugs after radiochemotherapy, so that more patients can obtain clinical benefits in this situation .

Dr.
Perez pointed out that the ongoing research on induction or simultaneous anti-PD-(L)1 studies will be difficult to compare because there are substantial differences among eligible populations .

However, there are still some shortcomings in the current research.
Dr.
Spiegel and others are investigating the joint research of the PACIFIC regimen with different radiochemotherapy regimens and other drugs after radiochemotherapy, so that more patients can obtain clinical benefits in this situation .
Dr.
Perez pointed out that the ongoing research on induction or simultaneous anti-PD-(L)1 studies will be difficult to compare because there are substantial differences among eligible populations .
The ongoing research on induction or simultaneous anti-PD-(L)1 studies will be difficult to compare because there are substantial differences among eligible populations
.
The ongoing research on induction or simultaneous anti-PD-(L)1 studies will be difficult to compare because there are substantial differences among eligible populations
.
In the PACIFIC study, patients were enrolled after the completion of concurrent radiotherapy and chemotherapy, so they did not progress in the initial treatment.
They also maintained a good performance state after radiotherapy and chemotherapy, with a WHO status of 0 or 1
.
Therefore, this is a relatively suitable cohort of patients, and it is difficult to compare with studies in which patients were included before the start of concurrent chemotherapy and radiotherapy
.
In the PACIFIC study, patients were enrolled after the completion of concurrent radiotherapy and chemotherapy, so they did not progress in the initial treatment.
They also maintained a good performance state after radiotherapy and chemotherapy, with a WHO status of 0 or 1
.
Therefore, this is a relatively suitable cohort of patients, and it is difficult to compare with studies in which patients were included before the start of concurrent chemotherapy and radiotherapy
.
Leave a message here